Bowen Hanes & Co. Inc. Purchases 3,236 Shares of Eli Lilly and Company (NYSE:LLY)

Bowen Hanes & Co. Inc. increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 128,550 shares of the company's stock after purchasing an additional 3,236 shares during the quarter. Eli Lilly and Company accounts for 2.7% of Bowen Hanes & Co. Inc.'s holdings, making the stock its 7th biggest holding. Bowen Hanes & Co. Inc.'s holdings in Eli Lilly and Company were worth $99,241,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of LLY. Skandinaviska Enskilda Banken AB publ grew its position in Eli Lilly and Company by 1.4% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 336,599 shares of the company's stock valued at $260,474,000 after acquiring an additional 4,722 shares during the last quarter. Tredje AP fonden grew its position in Eli Lilly and Company by 15.9% in the 4th quarter. Tredje AP fonden now owns 240,123 shares of the company's stock valued at $185,375,000 after acquiring an additional 33,020 shares during the last quarter. Avantax Advisory Services Inc. grew its position in Eli Lilly and Company by 10.7% in the 4th quarter. Avantax Advisory Services Inc. now owns 51,279 shares of the company's stock valued at $39,587,000 after acquiring an additional 4,937 shares during the last quarter. Essential Planning LLC. grew its position in Eli Lilly and Company by 6,406.9% in the 4th quarter. Essential Planning LLC. now owns 716,081 shares of the company's stock valued at $593,544,000 after acquiring an additional 705,076 shares during the last quarter. Finally, Egerton Capital UK LLP bought a new position in Eli Lilly and Company in the 4th quarter valued at $216,917,000. Institutional investors own 82.53% of the company's stock.

Remove Ads

Eli Lilly and Company Stock Down 2.9 %

Shares of NYSE LLY traded down $23.47 during mid-day trading on Thursday, reaching $798.39. 3,564,332 shares of the company were exchanged, compared to its average volume of 3,129,621. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The stock has a market cap of $757.01 billion, a price-to-earnings ratio of 68.18, a P/E/G ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53. The firm has a 50-day moving average of $830.18 and a 200 day moving average of $844.96.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company declared that its Board of Directors has authorized a share repurchase plan on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board believes its shares are undervalued.

Wall Street Analyst Weigh In

Several equities analysts have commented on LLY shares. Wells Fargo & Company upped their price objective on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Citigroup cut their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. StockNews.com raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Truist Financial upped their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a report on Monday, February 3rd. Finally, Wolfe Research assumed coverage on Eli Lilly and Company in a report on Friday, November 15th. They issued an "outperform" rating and a $1,000.00 target price for the company. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $1,009.72.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.